Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement from the American Heart Association and Neurocritical Care Society.

"Disclosures Writing Group DisclosuresWriting group memberEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOtherKaren G. HirschStanford UniversityNIH (has grant­funding from the NIH to study post–cardiac arrest brain injury)†NoneNoneNoneNoneNoneNoneRomergryko G. GeocadinJohns Hopkins University School of MedicineNIH (grants to his institution for research)†NoneNoneMedicolegal expert consultant*NoneNoneJohns Hopkins University (professor)†Benjamin S. AbellaUniversity of PennsylvaniaNoneNoneBecton Dickinson†; Zoll†; Stryker*NoneNeuroptics*Becton Dickinson†; Zoll†NoneEdilberto AmorimUniversity of California, San Francisco–Weill Institute for NeurosciencesAHA (career development award [CDA and AMFDP])†; NIH (career development award [K23])†; Zoll Foundation†; Hellman Foundation†; Regents of the University of California†; Cures Within Reach†; Cure Epilepsy†NoneNoneNoneNoneNoneNoneMary Kay BaderProvidence Mission Hospital Nursing Center of Excellence/Critical Care ServicesNoneNoneCeribell†; Neuroptics*; BD*NoneNeuroptics*NoneNoneJeffrey F. BarlettaMidwestern UniversityNoneSociety of Critical Care Medicine (He is an elected member of SCCM Council)*NoneNoneNoneWolters Kluwer*NoneKatherine BergBeth Israel Deaconess Medical CenterNoneNoneNoneNoneNoneAHA/ILCOR†NoneClifton W. CallawayUniversity of PittsburghNoneNoneNoneNoneNoneNoneNoneHans FribergSkane University Hospital (Sweden)NoneNoneNoneNoneNoneNoneNoneEmily J. GilmoreYale University School of MedicineNoneNoneNoneNoneNonecarpl.ai†; AAN*NoneDavid M. GreerBoston University School of MedicineNoneNoneNoneNoneNoneNoneNoneKarl B. KernSarver Heart Center, University of ArizonaNoneNoneNoneNoneNoneNoneNoneSarah LivesayRush University College of NursingNoneNoneNoneBaptist Health South Florida*; Scott and Patton, PC†Stroke Challenges, LLC*NoneNoneTeresa L. MayMaine Medical CenterNoneNoneNoneNoneNoneNoneNoneRobert W. NeumarUniversity of MichiganNIH†; AHA†; Laerdal Foundation*NoneNoneNoneNoneNoneNoneJerry P. NolanWarwick Medical School, University of Warwick; Royal United Hospital (United Kingdom)NIHR (grants for PARAMEDIC-3 and AIRWAYS-3 trials)*NoneNoneNoneNoneNoneNoneMauro OddoCHUV-Lausanne University Hospital (Switzerland)NoneNoneNoneNoneNoneNoneNoneMary Ann PeberdyVirginia Commonwealth UniversityNoneNoneNoneNoneNoneNoneNoneSamuel M. PoloyacUniversity of Texas at AustinNoneNoneNoneNoneNoneNoneNoneDavid SederMaine Medical CenterNIGMS (PI of Adenosinergic Signaling in the Immunoinflammatory Response After Cardiac Arrest under NIGMS 1P20GM139745-01 [5491])†NoneNoneNoneNoneNoneNoneFabio Silvio TacconeHopital Universitaire de Bruxelles (Belgium)NoneNoneNoneNoneNoneNEUROPTICS*; NIHON KHODEN*NoneAnezi UzenduSt. Luke’s Mid America Heart InstituteNoneNoneNoneNoneNoneNoneNoneBrian WalshUniversity of Texas Medical Branch School of Health SciencesSentec (IIR grant for EIT)†NoneMedtronic*Expert witness*FluidIQ†Medtronic*UTMB (associate professor)†Janice L. ZimmermanThe Methodist Hospital Physician OrganizationNoneNoneNoneNoneNoneNoneNoneThis table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition*Modest†Significant Reviewer DisclosuresReviewerEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOtherBernd W. BöttigerUniversity Hospital of Cologne (Germany)NoneNoneNoneNoneNoneNoneNoneAaron M. CookUniversity of Kentucky HealthcareNoneNoneNoneNoneNoneNoneNoneCarolina B. MacielUniversity of FloridaAHA (postanoxic status epilepticus pilot trial grant)†NoneAmerican Academy of Neurology*NoneNoneNoneNoneStephan A. MayerNew York Medical CollegeNoneNoneCeribell*NoneNoneNoneNoneJasmeet SoarSouthmead Hospital/North Bristol NHS Trust (United Kingdom)NoneNoneNoneNoneNoneNoneNoneThis table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition*Modest†Significant Writing Group Disclosures Writing group memberEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOtherKaren G. HirschStanford UniversityNIH (has grant­funding from the NIH to study post–cardiac arrest brain injury)†NoneNoneNoneNoneNoneNoneRomergryko G. GeocadinJohns Hopkins University School of MedicineNIH (grants to his institution for research)†NoneNoneMedicolegal expert consultant*NoneNoneJohns Hopkins University (professor)†Benjamin S. AbellaUniversity of PennsylvaniaNoneNoneBecton Dickinson†; Zoll†; Stryker*NoneNeuroptics*Becton Dickinson†; Zoll†NoneEdilberto AmorimUniversity of California, San Francisco–Weill Institute for NeurosciencesAHA (career development award [CDA and AMFDP])†; NIH (career development award [K23])†; Zoll Foundation†; Hellman Foundation†; Regents of the University of California†; Cures Within Reach†; Cure Epilepsy†NoneNoneNoneNoneNoneNoneMary Kay BaderProvidence Mission Hospital Nursing Center of Excellence/Critical Care ServicesNoneNoneCeribell†; Neuroptics*; BD*NoneNeuroptics*NoneNoneJeffrey F. BarlettaMidwestern UniversityNoneSociety of Critical Care Medicine (He is an elected member of SCCM Council)*NoneNoneNoneWolters Kluwer*NoneKatherine BergBeth Israel Deaconess Medical CenterNoneNoneNoneNoneNoneAHA/ILCOR†NoneClifton W. CallawayUniversity of PittsburghNoneNoneNoneNoneNoneNoneNoneHans FribergSkane University Hospital (Sweden)NoneNoneNoneNoneNoneNoneNoneEmily J. GilmoreYale University School of MedicineNoneNoneNoneNoneNonecarpl.ai†; AAN*NoneDavid M. GreerBoston University School of MedicineNoneNoneNoneNoneNoneNoneNoneKarl B. KernSarver Heart Center, University of ArizonaNoneNoneNoneNoneNoneNoneNoneSarah LivesayRush University College of NursingNoneNoneNoneBaptist Health South Florida*; Scott and Patton, PC†Stroke Challenges, LLC*NoneNoneTeresa L. MayMaine Medical CenterNoneNoneNoneNoneNoneNoneNoneRobert W. NeumarUniversity of MichiganNIH†; AHA†; Laerdal Foundation*NoneNoneNoneNoneNoneNoneJerry P. NolanWarwick Medical School, University of Warwick; Royal United Hospital (United Kingdom)NIHR (grants for PARAMEDIC-3 and AIRWAYS-3 trials)*NoneNoneNoneNoneNoneNoneMauro OddoCHUV-Lausanne University Hospital (Switzerland)NoneNoneNoneNoneNoneNoneNoneMary Ann PeberdyVirginia Commonwealth UniversityNoneNoneNoneNoneNoneNoneNoneSamuel M. PoloyacUniversity of Texas at AustinNoneNoneNoneNoneNoneNoneNoneDavid SederMaine Medical CenterNIGMS (PI of Adenosinergic Signaling in the Immunoinflammatory Response After Cardiac Arrest under NIGMS 1P20GM139745-01 [5491])†NoneNoneNoneNoneNoneNoneFabio Silvio TacconeHopital Universitaire de Bruxelles (Belgium)NoneNoneNoneNoneNoneNEUROPTICS*; NIHON KHODEN*NoneAnezi UzenduSt. Luke’s Mid America Heart InstituteNoneNoneNoneNoneNoneNoneNoneBrian WalshUniversity of Texas Medical Branch School of Health SciencesSentec (IIR grant for EIT)†NoneMedtronic*Expert witness*FluidIQ†Medtronic*UTMB (associate professor)†Janice L. ZimmermanThe Methodist Hospital Physician OrganizationNoneNoneNoneNoneNoneNoneNoneThis table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition*Modest†Significant Reviewer Disclosures ReviewerEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOtherBernd W. BöttigerUniversity Hospital of Cologne (Germany)NoneNoneNoneNoneNoneNoneNoneAaron M. CookUniversity of Kentucky HealthcareNoneNoneNoneNoneNoneNoneNoneCarolina B. MacielUniversity of FloridaAHA (postanoxic status epilepticus pilot trial grant)†NoneAmerican Academy of Neurology*NoneNoneNoneNoneStephan A. MayerNew York Medical CollegeNoneNoneCeribell*NoneNoneNoneNoneJasmeet SoarSouthmead Hospital/North Bristol NHS Trust (United Kingdom)NoneNoneNoneNoneNoneNoneNoneThis table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair"